Form 4: Lixte Biotechnology Director Yun Yen Acquires 4,545 Shares Through Stock Options

Director Yun Yen of Lixte Biotechnology Holdings, Inc. acquired 4,545 shares through stock options as part of their board compensation.

Summary

• Yun Yen, a director at Lixte Biotechnology Holdings, Inc., was granted stock options to purchase 4,545 shares on January 20, 2025.
• These options were granted in lieu of quarterly cash compensation under the Board Compensation Plan.
• The options have an exercise price of $2.33 and vest immediately.
• The director also holds other options and warrants with varying exercise prices and expiration dates.
• These include options to purchase 5,786 shares at $1.30 expiring on September 30, 2029, and options to purchase 10,000 shares at $2.37 expiring on June 30, 2029.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed neutrally to slightly positive as it aligns interests. There are no indications of any negative or unexpected events.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The immediate vesting of the options provides an immediate incentive for the director.

Management Comments

• The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.

Industry Context

This is a standard practice for compensating board members in publicly traded companies, particularly in the biotechnology sector where stock options are often used to align interests with long-term growth.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors in the biotechnology industry.
• The vesting schedule of immediately vesting options is not unusual for board members.
• The exercise price of $2.33 is specific to Lixte Biotechnology's stock price at the time of the grant.

Stakeholder Impact

• The stock option grant may have a minor dilutive effect on existing shareholders.
• The grant aligns the director's interests with the long-term success of the company, which is beneficial for shareholders.

Key Dates

Keywords

stock options, director compensation, insider trading, Lixte Biotechnology, equity, Yun Yen, LIXT